a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.

The global Urological Cancer Therapeutics Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Urological Cancer Therapeutics Drugs in various end use industries. The expanding demands from the Hospital, Medical Research Laboratory and Others,, are propelling Urological Cancer Therapeutics Drugs market. Xofigo (radium Ra 223 dichloride), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Jevtana (cabazitaxel) segment is estimated at % CAGR for the next seven-year period.

Asia Pacific shows high growth potential for Urological Cancer Therapeutics Drugs market, driven by demand from China, the second largest economy with some signs of stabilising, the Urological Cancer Therapeutics Drugs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Urological Cancer Therapeutics Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Urological Cancer Therapeutics Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Urological Cancer Therapeutics Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Urological Cancer Therapeutics Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Urological Cancer Therapeutics Drugs covered in this report include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc.

The global Urological Cancer Therapeutics Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline plc

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

Scope of Urological Cancer Therapeutics Drugs - Market Report

Report Metric	Details
Report Name	Urological Cancer Therapeutics Drugs - Market
Forecasted market size in 2025	$ 48.6 billion
Forecasted years	2023 - 2025
Global Urological Cancer Therapeutics Drugs market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Urological Cancer Therapeutics Drugs market, Segment by Type:	Xofigo (radium Ra 223 dichloride) Jevtana (cabazitaxel) Inlyta (axitinib) Votrient (pazopanib hydrochloride) Sutent (sunitinib malate) Zytiga (abiraterone acetate) Xtandi (enzalutamide) Opdivo (nivolumab) Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs market, by Application	Hospital Medical Research Laboratory Others
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Urological Cancer Therapeutics Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What is the Urological Cancer Therapeutics Drugs - Market size in 2025?

Ans: The Urological Cancer Therapeutics Drugs - Market size in 2025 will be $ 48.6 billion.

What are the Application segmentation covered in the Urological Cancer Therapeutics Drugs - Market report?

Ans: The Applications covered in the Urological Cancer Therapeutics Drugs - Market report are Hospital, Medical Research Laboratory, Others

What are the Type segmentation covered in the Urological Cancer Therapeutics Drugs - Market report?

Ans: The Types covered in the Urological Cancer Therapeutics Drugs - Market report are Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib), Votrient (pazopanib hydrochloride), Sutent (sunitinib malate), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Opdivo (nivolumab), Provenge (sipuleucel-T)

1 Market Overview of Urological Cancer Therapeutics Drugs

1.1 Urological Cancer Therapeutics Drugs Market Overview

1.1.1 Urological Cancer Therapeutics Drugs Product Scope

1.1.2 Urological Cancer Therapeutics Drugs Market Status and Outlook

1.2 Global Urological Cancer Therapeutics Drugs Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Urological Cancer Therapeutics Drugs Market Size by Region (2018-2029)

1.4 Global Urological Cancer Therapeutics Drugs Historic Market Size by Region (2018-2023)

1.5 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Urological Cancer Therapeutics Drugs Market Size (2018-2029)

1.6.1 North America Urological Cancer Therapeutics Drugs Market Size (2018-2029)

1.6.2 Europe Urological Cancer Therapeutics Drugs Market Size (2018-2029)

1.6.3 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size (2018-2029)

1.6.4 Latin America Urological Cancer Therapeutics Drugs Market Size (2018-2029)

1.6.5 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size (2018-2029)

2 Urological Cancer Therapeutics Drugs Market by Type

2.1 Introduction

2.1.1 Xofigo (radium Ra 223 dichloride)

2.1.2 Jevtana (cabazitaxel)

2.1.3 Inlyta (axitinib)

2.1.4 Votrient (pazopanib hydrochloride)

2.1.5 Sutent (sunitinib malate)

2.1.6 Zytiga (abiraterone acetate)

2.1.7 Xtandi (enzalutamide)

2.1.8 Opdivo (nivolumab)

2.1.9 Provenge (sipuleucel-T)

2.2 Global Urological Cancer Therapeutics Drugs Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Type (2018-2023)

2.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Breakdown by Type (2018-2029)

3 Urological Cancer Therapeutics Drugs Market Overview by Application

3.1 Introduction

3.1.1 Hospital

3.1.2 Medical Research Laboratory

3.1.3 Others

3.2 Global Urological Cancer Therapeutics Drugs Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Urological Cancer Therapeutics Drugs Historic Market Size by Application (2018-2023)

3.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Breakdown by Application (2018-2029)

4 Urological Cancer Therapeutics Drugs Competition Analysis by Players

4.1 Global Urological Cancer Therapeutics Drugs Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2022)

4.3 Date of Key Players Enter into Urological Cancer Therapeutics Drugs Market

4.4 Global Top Players Urological Cancer Therapeutics Drugs Headquarters and Area Served

4.5 Key Players Urological Cancer Therapeutics Drugs Product Solution and Service

4.6 Competitive Status

4.6.1 Urological Cancer Therapeutics Drugs Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 Novartis

5.1.1 Novartis Profile

5.1.2 Novartis Main Business

5.1.3 Novartis Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.1.4 Novartis Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.1.5 Novartis Recent Developments

5.2 Pfizer

5.2.1 Pfizer Profile

5.2.2 Pfizer Main Business

5.2.3 Pfizer Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.2.4 Pfizer Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.2.5 Pfizer Recent Developments

5.3 Johnson & Johnson

5.3.1 Johnson & Johnson Profile

5.3.2 Johnson & Johnson Main Business

5.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.3.5 AstraZeneca Recent Developments

5.4 AstraZeneca

5.4.1 AstraZeneca Profile

5.4.2 AstraZeneca Main Business

5.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.4.5 AstraZeneca Recent Developments

5.5 Astellas

5.5.1 Astellas Profile

5.5.2 Astellas Main Business

5.5.3 Astellas Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.5.4 Astellas Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.5.5 Astellas Recent Developments

5.6 Bristol-Myers Squibb

5.6.1 Bristol-Myers Squibb Profile

5.6.2 Bristol-Myers Squibb Main Business

5.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.6.5 Bristol-Myers Squibb Recent Developments

5.7 Abbott Laboratories

5.7.1 Abbott Laboratories Profile

5.7.2 Abbott Laboratories Main Business

5.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.7.5 Abbott Laboratories Recent Developments

5.8 Celgene Corporation

5.8.1 Celgene Corporation Profile

5.8.2 Celgene Corporation Main Business

5.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.8.5 Celgene Corporation Recent Developments

5.9 Dendreon Corporation

5.9.1 Dendreon Corporation Profile

5.9.2 Dendreon Corporation Main Business

5.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.9.5 Dendreon Corporation Recent Developments

5.10 Ferring Pharmaceuticals

5.10.1 Ferring Pharmaceuticals Profile

5.10.2 Ferring Pharmaceuticals Main Business

5.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.10.5 Ferring Pharmaceuticals Recent Developments

5.11 GlaxoSmithKline plc

5.11.1 GlaxoSmithKline plc Profile

5.11.2 GlaxoSmithKline plc Main Business

5.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.11.5 GlaxoSmithKline plc Recent Developments

5.12 Indevus Pharmaceuticals Inc

5.12.1 Indevus Pharmaceuticals Inc Profile

5.12.2 Indevus Pharmaceuticals Inc Main Business

5.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.12.5 Indevus Pharmaceuticals Inc Recent Developments

5.13 Ipsen

5.13.1 Ipsen Profile

5.13.2 Ipsen Main Business

5.13.3 Ipsen Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.13.4 Ipsen Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.13.5 Ipsen Recent Developments

5.14 Roche Healthcare

5.14.1 Roche Healthcare Profile

5.14.2 Roche Healthcare Main Business

5.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.14.5 Roche Healthcare Recent Developments

5.15 Sanofi S.A.

5.15.1 Sanofi S.A. Profile

5.15.2 Sanofi S.A. Main Business

5.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Products, Services and Solutions

5.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Revenue (US$ Million) & (2018-2023)

5.15.5 Sanofi S.A. Recent Developments

6 North America

6.1 North America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)

6.2 U.S.

6.3 Canada

7 Europe

7.1 Europe Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Urological Cancer Therapeutics Drugs Market Dynamics

11.1 Urological Cancer Therapeutics Drugs Industry Trends

11.2 Urological Cancer Therapeutics Drugs Market Drivers

11.3 Urological Cancer Therapeutics Drugs Market Challenges

11.4 Urological Cancer Therapeutics Drugs Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

FEATURED COMPANIES

Ferring Pharmaceuticals

GlaxoSmithKline PLC

Indevus Pharmaceuticals Inc

Ipsen S A

Roche Healthcare

Sanofi

List of Tables

Table 1. Global Market Urological Cancer Therapeutics Drugs Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Urological Cancer Therapeutics Drugs Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Urological Cancer Therapeutics Drugs Market Size Share by Region (2018-2023)

Table 4. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Urological Cancer Therapeutics Drugs Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Urological Cancer Therapeutics Drugs Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2023)

Table 9. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2024-2029)

Table 11. North America Urological Cancer Therapeutics Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Urological Cancer Therapeutics Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Urological Cancer Therapeutics Drugs Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2023)

Table 24. Global Urological Cancer Therapeutics Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2024-2029)

Table 26. North America Urological Cancer Therapeutics Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Urological Cancer Therapeutics Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2022)

Table 39. Date of Key Players Enter into Urological Cancer Therapeutics Drugs Market

Table 40. Global Urological Cancer Therapeutics Drugs Key Players Headquarters and Area Served

Table 41. Urological Cancer Therapeutics Drugs Product Solution and Service

Table 42. Global Urological Cancer Therapeutics Drugs Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. Novartis Basic Information List

Table 45. Novartis Description and Business Overview

Table 46. Novartis Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 47. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Novartis (2018-2023)

Table 48. Novartis Recent Developments

Table 49. Pfizer Basic Information List

Table 50. Pfizer Description and Business Overview

Table 51. Pfizer Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 52. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Pfizer (2018-2023)

Table 53. Pfizer Recent Developments

Table 54. Johnson & Johnson Basic Information List

Table 55. Johnson & Johnson Description and Business Overview

Table 56. Johnson & Johnson Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 57. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Johnson & Johnson (2018-2023)

Table 58. Johnson & Johnson Recent Developments

Table 59. AstraZeneca Basic Information List

Table 60. AstraZeneca Description and Business Overview

Table 61. AstraZeneca Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 62. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of AstraZeneca (2018-2023)

Table 63. AstraZeneca Recent Developments

Table 64. Astellas Basic Information List

Table 65. Astellas Description and Business Overview

Table 66. Astellas Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 67. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Astellas (2018-2023)

Table 68. Astellas Recent Developments

Table 69. Bristol-Myers Squibb Basic Information List

Table 70. Bristol-Myers Squibb Description and Business Overview

Table 71. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 72. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Bristol-Myers Squibb (2018-2023)

Table 73. Bristol-Myers Squibb Recent Developments

Table 74. Abbott Laboratories Basic Information List

Table 75. Abbott Laboratories Description and Business Overview

Table 76. Abbott Laboratories Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 77. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Abbott Laboratories (2018-2023)

Table 78. Abbott Laboratories Recent Developments

Table 79. Celgene Corporation Basic Information List

Table 80. Celgene Corporation Description and Business Overview

Table 81. Celgene Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 82. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Celgene Corporation (2018-2023)

Table 83. Celgene Corporation Recent Developments

Table 84. Dendreon Corporation Basic Information List

Table 85. Dendreon Corporation Description and Business Overview

Table 86. Dendreon Corporation Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 87. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Dendreon Corporation (2018-2023)

Table 88. Dendreon Corporation Recent Developments

Table 89. Ferring Pharmaceuticals Basic Information List

Table 90. Ferring Pharmaceuticals Description and Business Overview

Table 91. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 92. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Ferring Pharmaceuticals (2018-2023)

Table 93. Ferring Pharmaceuticals Recent Developments

Table 94. GlaxoSmithKline plc Basic Information List

Table 95. GlaxoSmithKline plc Description and Business Overview

Table 96. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 97. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of GlaxoSmithKline plc (2018-2023)

Table 98. GlaxoSmithKline plc Recent Developments

Table 99. Indevus Pharmaceuticals Inc Basic Information List

Table 100. Indevus Pharmaceuticals Inc Description and Business Overview

Table 101. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 102. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Indevus Pharmaceuticals Inc (2018-2023)

Table 103. Indevus Pharmaceuticals Inc Recent Developments

Table 104. Ipsen Basic Information List

Table 105. Ipsen Description and Business Overview

Table 106. Ipsen Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 107. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Ipsen (2018-2023)

Table 108. Ipsen Recent Developments

Table 109. Roche Healthcare Basic Information List

Table 110. Roche Healthcare Description and Business Overview

Table 111. Roche Healthcare Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 112. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Roche Healthcare (2018-2023)

Table 113. Roche Healthcare Recent Developments

Table 114. Sanofi S.A. Basic Information List

Table 115. Sanofi S.A. Description and Business Overview

Table 116. Sanofi S.A. Urological Cancer Therapeutics Drugs Products, Services and Solutions

Table 117. Revenue (US$ Million) in Urological Cancer Therapeutics Drugs Business of Sanofi S.A. (2018-2023)

Table 118. Sanofi S.A. Recent Developments

Table 119. North America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 120. North America Urological Cancer Therapeutics Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 121. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 122. Europe Urological Cancer Therapeutics Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 123. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 124. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2018-2023) & (US$ Million)

Table 125. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size by Region (2024-2029) & (US$ Million)

Table 126. Asia-Pacific Urological Cancer Therapeutics Drugs Market Share by Region (2018-2023)

Table 127. Asia-Pacific Urological Cancer Therapeutics Drugs Market Share by Region (2024-2029)

Table 128. Latin America Urological Cancer Therapeutics Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 129. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 130. Latin America Urological Cancer Therapeutics Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 131. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 132. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 133. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 134. Urological Cancer Therapeutics Drugs Market Trends

Table 135. Urological Cancer Therapeutics Drugs Market Drivers

Table 136. Urological Cancer Therapeutics Drugs Market Challenges

Table 137. Urological Cancer Therapeutics Drugs Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Urological Cancer Therapeutics Drugs Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Urological Cancer Therapeutics Drugs Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Urological Cancer Therapeutics Drugs Market Share by Regions: 2022 VS 2029

Figure 4. Global Urological Cancer Therapeutics Drugs Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Urological Cancer Therapeutics Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Urological Cancer Therapeutics Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Urological Cancer Therapeutics Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Urological Cancer Therapeutics Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Urological Cancer Therapeutics Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of Xofigo (radium Ra 223 dichloride)

Figure 11. Global Xofigo (radium Ra 223 dichloride) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of Jevtana (cabazitaxel)

Figure 13. Global Jevtana (cabazitaxel) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Product Picture of Inlyta (axitinib)

Figure 15. Global Inlyta (axitinib) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 16. Product Picture of Votrient (pazopanib hydrochloride)

Figure 17. Global Votrient (pazopanib hydrochloride) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 18. Product Picture of Sutent (sunitinib malate)

Figure 19. Global Sutent (sunitinib malate) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 20. Product Picture of Zytiga (abiraterone acetate)

Figure 21. Global Zytiga (abiraterone acetate) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 22. Product Picture of Xtandi (enzalutamide)

Figure 23. Global Xtandi (enzalutamide) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 24. Product Picture of Opdivo (nivolumab)

Figure 25. Global Opdivo (nivolumab) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 26. Product Picture of Provenge (sipuleucel-T)

Figure 27. Global Provenge (sipuleucel-T) Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 28. Global Urological Cancer Therapeutics Drugs Market Size Share by Type: 2022 & 2029

Figure 29. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2029)

Figure 30. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2029)

Figure 31. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2029)

Figure 32. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2029)

Figure 33. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2018-2029)

Figure 34. Hospital Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 35. Medical Research Laboratory Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 36. Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 37. Global Urological Cancer Therapeutics Drugs Market Size Share by Application: 2022 & 2029

Figure 38. North America Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2029)

Figure 39. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2029)

Figure 40. Asia-Pacific Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2029)

Figure 41. Latin America Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2029)

Figure 42. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2018-2029)

Figure 43. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 44. Global Top 5 and Top 10 Players Urological Cancer Therapeutics Drugs Market Share in 2022

Figure 45. North America Urological Cancer Therapeutics Drugs Market Share by Country (2018-2029)

Figure 46. U.S. Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 47. Canada Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 48. Germany Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 49. France Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 50. U.K. Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 51. Italy Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 52. Russia Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 53. Nordic Countries Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 54. Asia-Pacific Urological Cancer Therapeutics Drugs Market Share by Region (2018-2029)

Figure 55. China Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 56. Japan Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 57. South Korea Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 58. Southeast Asia Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 59. India Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 60. Australia Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 61. Latin America Urological Cancer Therapeutics Drugs Market Share by Country (2018-2029)

Figure 62. Mexico Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 63. Brazil Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 64. Middle East & Africa Urological Cancer Therapeutics Drugs Market Share by Country (2018-2029)

Figure 65. Turkey Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 66. Saudi Arabia Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 67. UAE Urological Cancer Therapeutics Drugs Market Size (2018-2029) & (US$ Million)

Figure 68. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3350

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions